Latest news
Replimune Group, Inc. (REPL) Investors Who Suffered Losses - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 22:21:29 GMTFDA staff poke holes in Replimune's efficacy case for melanoma drug - FirstWord PHARMAFirstWord PHARMA · Tue, 28 Jul 2026 21:10:16 GMTHD-Oslo Forum Briefing Paper “Cooling the heat: mediation in a warming world” - hdcentre.orghdcentre.org · Tue, 28 Jul 2026 10:26:29 GMTCapricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 28 Jul 2026 07:00:00 GMTFDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm - BioSpaceBioSpace · Tue, 28 Jul 2026 07:00:00 GMTCapricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - TradingViewTradingView · Mon, 27 Jul 2026 15:39:15 GMTUPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMTCapricor Therapeutics shares plunge after FDA releases briefing documents - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT